Literature DB >> 20006993

A tale of tails: Sialidase is key to success in a model of phage therapy against K1-capsulated Escherichia coli.

J J Bull1, E R Vimr, I J Molineux.   

Abstract

Prior studies treating mice infected with Escherichia coli O18:K1:H7 observed that phages requiring the K1 capsule for infection (K1-dep) were superior to capsule-independent (K1-ind) phages. We show that three K1-ind phages all have low fitness when grown on cells in serum whereas fitnesses of four K1-dep phages were high. The difference is serum-specific, as fitnesses in broth overlapped. Sialidase activity was associated with all K1-dep virions tested but no K1-ind virions, a phenotype supported by sequence analyses. Adding endosialidase to cells infected with K1-ind phage increased fitness in serum by enhancing productive infection after adsorption. We propose that virion sialidase activity is the primary determinant of high fitness on cells grown in serum, and thus in a mammalian host. Although the benefit of sialidase is specific to K1-capsulated bacteria, this study may provide a scientific rationale for selecting phages for therapeutic use in many systemic infections. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20006993      PMCID: PMC2843586          DOI: 10.1016/j.virol.2009.11.040

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  50 in total

Review 1.  Pharmacokinetic principles of bacteriophage therapy.

Authors:  Robert J H Payne; Vincent A A Jansen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Phage offer a real alternative.

Authors:  Gary K Schoolnik; William C Summers; James D Watson
Journal:  Nat Biotechnol       Date:  2004-05       Impact factor: 54.908

3.  Therapeutic use of bacteriophages.

Authors:  James Soothill; Catherine Hawkins; Erik Anggård; David Harper
Journal:  Lancet Infect Dis       Date:  2004-09       Impact factor: 25.071

4.  Phage therapy: an attractive option for dealing with antibiotic-resistant bacterial infections.

Authors:  Alexander Sulakvelidze
Journal:  Drug Discov Today       Date:  2005-06-15       Impact factor: 7.851

5.  Evolution of bacteriophages infecting encapsulated bacteria: lessons from Escherichia coli K1-specific phages.

Authors:  Katharina Stummeyer; David Schwarzer; Heike Claus; Ulrich Vogel; Rita Gerardy-Schahn; Martina Mühlenhoff
Journal:  Mol Microbiol       Date:  2006-06       Impact factor: 3.501

Review 6.  Novel approaches to developing new antibiotics for bacterial infections.

Authors:  A R M Coates; Y Hu
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

7.  Separate pathways for O acetylation of polymeric and monomeric sialic acids and identification of sialyl O-acetyl esterase in Escherichia coli K1.

Authors:  Susan M Steenbergen; Young-Choon Lee; Willie F Vann; Justine Vionnet; Lori F Wright; Eric R Vimr
Journal:  J Bacteriol       Date:  2006-09       Impact factor: 3.490

8.  Latent pathway activation and increased pathway capacity enable Escherichia coli adaptation to loss of key metabolic enzymes.

Authors:  Stephen S Fong; Annik Nanchen; Bernhard O Palsson; Uwe Sauer
Journal:  J Biol Chem       Date:  2005-11-30       Impact factor: 5.157

9.  Characterization of bacteriophages used in the Salmonella enterica serovar Enteritidis phage-typing scheme.

Authors:  N De Lappe; G Doran; J O'Connor; C O'Hare; M Cormican
Journal:  J Med Microbiol       Date:  2009-01       Impact factor: 2.472

10.  In vivo replication of T4 and T7 bacteriophages in germ-free mice colonized with Escherichia coli.

Authors:  Marietta Weiss; Emmanuel Denou; Anne Bruttin; Ruth Serra-Moreno; Marie-Lise Dillmann; Harald Brüssow
Journal:  Virology       Date:  2009-08-21       Impact factor: 3.616

View more
  22 in total

1.  Complete genome sequence of the novel Escherichia coli phage phAPEC8.

Authors:  J Tsonos; E M Adriaenssens; J Klumpp; J-P Hernalsteens; R Lavigne; H De Greve
Journal:  J Virol       Date:  2012-12       Impact factor: 5.103

2.  In vivo growth rates are poorly correlated with phage therapy success in a mouse infection model.

Authors:  J J Bull; G Otto; I J Molineux
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

3.  The phenotype-fitness map in experimental evolution of phages.

Authors:  James J Bull; Richard H Heineman; Claus O Wilke
Journal:  PLoS One       Date:  2011-11-22       Impact factor: 3.240

4.  Three-dimensional reconstructions of the bacteriophage CUS-3 virion reveal a conserved coat protein I-domain but a distinct tailspike receptor-binding domain.

Authors:  Kristin N Parent; Jinghua Tang; Giovanni Cardone; Eddie B Gilcrease; Mandy E Janssen; Norman H Olson; Sherwood R Casjens; Timothy S Baker
Journal:  Virology       Date:  2014-07-18       Impact factor: 3.616

5.  Molecular characterization, structural analysis and determination of host range of a novel bacteriophage LSB-1.

Authors:  Yaming Chai; Hongyan Xiong; Xiangyu Ma; Liqing Cheng; Guorong Huang; Zhonglin Rao Lin Zhang
Journal:  Virol J       Date:  2010-09-28       Impact factor: 4.099

6.  Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms.

Authors:  Quan-Guo Zhang; Angus Buckling
Journal:  Evol Appl       Date:  2012-01-13       Impact factor: 5.183

7.  The T7-related Pseudomonas putida phage φ15 displays virion-associated biofilm degradation properties.

Authors:  Anneleen Cornelissen; Pieter-Jan Ceyssens; Jeroen T'Syen; Helena Van Praet; Jean-Paul Noben; Olga V Shaburova; Victor N Krylov; Guido Volckaert; Rob Lavigne
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

Review 8.  Bacteriophages and phage-derived proteins--application approaches.

Authors:  Zuzanna Drulis-Kawa; Grazyna Majkowska-Skrobek; Barbara Maciejewska
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

9.  Phage fitness may help predict phage therapy efficacy.

Authors:  Heather M Lindberg; Kurt A McKean; Ing-Nang Wang
Journal:  Bacteriophage       Date:  2014-12-15

10.  Evolutionary principles and synthetic biology: avoiding a molecular tragedy of the commons with an engineered phage.

Authors:  Eric G Gladstone; Ian J Molineux; James J Bull
Journal:  J Biol Eng       Date:  2012-09-04       Impact factor: 4.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.